NCT01520051View on ClinicalTrials.gov

Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations

PHASE3UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

March 31, 2014

Conditions
AsthmaViral Infection
Interventions
DRUG

Mepolizumab

3 monthly intravenous infusions of 750 mg

DRUG

Placebo

3 monthly intravenous infusions with saline

Trial Locations (1)

1105 AZ

RECRUITING

Academic Medical Center, Amsterdam

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

The Netherlands Asthma Foundation

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT01520051 - Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations | Biotech Hunter | Biotech Hunter